<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: government regulation", fill: "#635147"},
{source: "3: government regulation", target: "3: ongoing research", fill: "#635147"},
{source: "3: ongoing research", target: "3: development preclinical testing", fill: "#635147"},
{source: "3: development preclinical testing", target: "3: clinical trial activities", fill: "#635147"},
{source: "3: clinical trial activities", target: "3: review by numerous governmental authorities both", fill: "#635147"},
{source: "3: government regulation", target: "5: regulations", fill: "#dc143c"},
{source: "5: regulations", target: "5: registration", fill: "#dc143c"},
{source: "5: registration", target: "5: manufacturing", fill: "#dc143c"},
{source: "5: manufacturing", target: "5: recordkeeping", fill: "#dc143c"},
{source: "5: regulations", target: "10: Subsequent ", fill: "#e52b50"},
{source: "10: Subsequent ", target: "10: discovery", fill: "#e52b50"},
{source: "10: discovery", target: "10: problems with", fill: "#e52b50"},
{source: "10: problems with", target: "10: product manufacturer", fill: "#e52b50"},
{source: "10: product manufacturer", target: "10: facility", fill: "#e52b50"},
{source: "10: facility", target: "10: restrictions on", fill: "#e52b50"},
{source: "10: restrictions on", target: "10: product manufacturer", fill: "#e52b50"},
{source: "10: product manufacturer", target: "10: product from", fill: "#e52b50"},
{source: "10: product from", target: "10: enforcement", fill: "#e52b50"},
{source: "10: Subsequent ", target: "19: governmental", fill: "#789"},
{source: "19: governmental", target: "19: regulations", fill: "#789"},
{source: "19: regulations", target: "19: participation", fill: "#789"},
{source: "19: participation", target: "19: reimbursement", fill: "#789"},
{source: "19: governmental", target: "30: The FDA ", fill: "#7d7"},
{source: "30: The FDA ", target: "30: also proposed", fill: "#7d7"},
{source: "30: also proposed", target: "30: additional regulations", fill: "#7d7"},
{source: "30: additional regulations", target: "30: would govern", fill: "#7d7"},
{source: "30: would govern", target: "30: distribution", fill: "#7d7"},
{source: "30: distribution", target: "30: allograft products", fill: "#7d7"},
{source: "30: The FDA ", target: "59: compete successfully", fill: "#8c92ac"},
{source: "59: compete successfully", target: "59: future against", fill: "#8c92ac"},
{source: "59: future against", target: "59: potential competitors", fill: "#8c92ac"},
{source: "59: potential competitors", target: "59: negatively", fill: "#8c92ac"},
{source: "59: negatively", target: "59: future growth", fill: "#8c92ac"},
{source: "59: future growth", target: "59: highly competitive", fill: "#8c92ac"},
{source: "59: highly competitive", target: "59: dominated by", fill: "#8c92ac"},
{source: "59: compete successfully", target: "60: prices offered by", fill: "#32cd32"},
{source: "60: prices offered by", target: "60: offered by", fill: "#32cd32"},
{source: "60: offered by", target: "60: competitors", fill: "#32cd32"},
{source: "60: competitors", target: "60: offer products", fill: "#32cd32"},
{source: "60: offer products", target: "60: desirable than", fill: "#32cd32"},
{source: "60: prices offered by", target: "62: market new products", fill: "#e25098"},
{source: "62: market new products", target: "62: technologies", fill: "#e25098"},
{source: "62: technologies", target: "62: products could become obsolete", fill: "#e25098"},
{source: "62: products could become obsolete", target: "62: would suffer", fill: "#e25098"},
{source: "62: would suffer", target: "62: continually", fill: "#e25098"},
{source: "62: continually", target: "62: product development", fill: "#e25098"},
{source: "62: product development", target: "62: improvement programs", fill: "#e25098"},
{source: "62: improvement programs", target: "62: new products represent", fill: "#e25098"},
{source: "62: new products represent", target: "62: significant", fill: "#e25098"},
{source: "62: significant", target: "62: growth rate", fill: "#e25098"},
{source: "62: market new products", target: "90: product liability", fill: "#ff2400"},
{source: "90: product liability", target: "90: brought against us", fill: "#ff2400"},
{source: "90: brought against us", target: "90: manufacture", fill: "#ff2400"},
{source: "90: manufacture", target: "90: medical devices exposes us", fill: "#ff2400"},
{source: "90: medical devices exposes us", target: "90: significant risk", fill: "#ff2400"},
{source: "90: product liability", target: "108: operations expose us", fill: "#d40000"},
{source: "108: operations expose us", target: "108: representatives agents", fill: "#d40000"},
{source: "108: representatives agents", target: "108: distributors", fill: "#d40000"},
{source: "108: distributors", target: "108: risks inherent", fill: "#d40000"},
{source: "108: risks inherent", target: "108: foreign jurisdictions", fill: "#d40000"},
{source: "108: operations expose us", target: "109: additional foreign governmental controls", fill: "#ff5a36"},
{source: "109: additional foreign governmental controls", target: "109: regulations on orthopaedic implants", fill: "#ff5a36"},
{source: "109: regulations on orthopaedic implants", target: "109: biologics products", fill: "#ff5a36"},
{source: "109: biologics products", target: "109: new export license requirements particularly", fill: "#ff5a36"},
{source: "109: new export license requirements particularly", target: "109: economic instability", fill: "#ff5a36"},
{source: "109: economic instability", target: "109: currency risk between", fill: "#ff5a36"},
{source: "109: currency risk between", target: "109: foreign currencies", fill: "#ff5a36"},
{source: "109: foreign currencies", target: "109: target markets", fill: "#ff5a36"},
{source: "109: target markets", target: "109: distributors", fill: "#ff5a36"},
{source: "109: distributors", target: "109: key personnel", fill: "#ff5a36"},
{source: "109: key personnel", target: "109: proprietary knowledge", fill: "#ff5a36"},
{source: "109: proprietary knowledge", target: "109: international markets", fill: "#ff5a36"},
{source: "109: international markets", target: "109: thirdparty reimbursement policy", fill: "#ff5a36"},
{source: "109: thirdparty reimbursement policy", target: "109: implant products", fill: "#ff5a36"},
{source: "109: implant products", target: "109: directly absorb medical costs", fill: "#ff5a36"},
{source: "109: directly absorb medical costs", target: "109: may necessitate", fill: "#ff5a36"},
{source: "109: may necessitate", target: "109: reducing selling prices", fill: "#ff5a36"},
{source: "109: reducing selling prices", target: "109: trade restrictions particularly", fill: "#ff5a36"},
{source: "109: trade restrictions particularly", target: "109: exportation", fill: "#ff5a36"},
{source: "109: exportation", target: "109: health care industry such as", fill: "#ff5a36"},
{source: "109: health care industry such as", target: "109: previously affected", fill: "#ff5a36"},
{source: "109: previously affected", target: "109: operations", fill: "#ff5a36"},
{source: "109: operations", target: "109: France Canada Korea ", fill: "#ff5a36"},
{source: "109: France Canada Korea ", target: "109: target markets particularly", fill: "#ff5a36"},
{source: "109: target markets particularly", target: "109: affecting", fill: "#ff5a36"},
{source: "109: affecting", target: "109: different", fill: "#ff5a36"},
{source: "109: additional foreign governmental controls", target: "START_HERE", fill: "#ff5a36"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Codes,_Rules_and_Regulations">New York Codes, Rules and Regulations</a></td>
      <td>The New York Codes, Rules and Regulations (NYCRR) contains New York state rules and regulations. The NYCRR is officially compiled by the New York State Department of State's Division of Administrative Rules.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_liability">Product liability</a></td>
      <td>Product liability is the area of law in which manufacturers, distributors, suppliers, retailers, and others who make products available to the public are held responsible for the injuries those products cause. Although the word "product" has broad connotations, product liability as an area of law is traditionally limited to products in the form of tangible personal property.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Diagnosis-related_group">Diagnosis-related group</a></td>
      <td>Diagnosis-related group (DRG) is a system to classify hospital cases into one of originally 467 groups, with the last group (coded as 470 through v24, 999 thereafter) being "Ungroupable". This system of classification was developed as a collaborative project by Robert B Fetter, PhD, of the Yale School of Management, and John D. Thompson, MPH, of the Yale School of Public Health.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Allotransplantation">Allotransplantation</a></td>
      <td>Allotransplant (allo- meaning "other" in Greek) is the transplantation of cells, tissues, or organs to a recipient from a genetically non-identical donor of the same species. The transplant is called an allograft, allogeneic transplant, or homograft.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Allograft_inflammatory_factor_1">Allograft inflammatory factor 1</a></td>
      <td>Allograft inflammatory factor 1 (AIF-1) also known as ionized calcium-binding adapter molecule 1 (IBA1) is a protein that in humans is encoded by the AIF1 gene.\n\n\n== Gene ==\nThe AIF1 gene is located within a segment of the major histocompatibility complex class III region.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Skin_grafting">Skin grafting</a></td>
      <td>Skin grafting, a type of graft surgery, involves the transplantation of skin. The transplanted tissue is called a skin graft.Surgeons may use skin grafting to treat:\n\nextensive wounding or trauma\nburns\nareas of extensive skin loss due to infection such as necrotizing fasciitis or purpura fulminans\nspecific surgeries that may require skin grafts for healing to occur - most commonly removal of skin cancersSkin grafting often takes place after serious injuries when some of the body's skin is damaged.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Axogen">Axogen</a></td>
      <td>Axogen is a developer of surgical solutions, including human tissue grafts,  based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Alloimmunity">Alloimmunity</a></td>
      <td>Alloimmunity (sometimes called isoimmunity) is an immune response to nonself antigens from members of the same species, which are called alloantigens or isoantigens. Two major types of alloantigens are blood group antigens and histocompatibility antigens.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Dancing_with_the_Stars_(American_TV_series)_competitors">List of Dancing with the Stars (American TV series) competitors</a></td>
      <td>Dancing with the Stars is an American reality television show in which celebrity contestants and professional dance partners compete to be the best dancers, as determined by the show's judges and public voting. The series first broadcast in 2005, and thirty complete seasons have aired on ABC. During each season, competitors are progressively eliminated on the basis of public voting and scores received from the judges until only a few contestants remain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dell_Technologies">Dell Technologies</a></td>
      <td>Dell Technologies Inc. is an American multinational technology company headquartered in Round Rock, Texas.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Legal_liability">Legal liability</a></td>
      <td>In law, liable means  "responsible or answerable in law; legally obligated". Legal liability concerns both civil law and criminal law and can arise from various areas of law, such as contracts, torts, taxes, or fines given by government agencies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Liability_insurance">Liability insurance</a></td>
      <td>Liability insurance (also called third-party insurance) is a part of the general insurance system of risk financing to protect the purchaser (the "insured") from the risks of liabilities imposed by lawsuits and similar claims and protects the insured if the purchaser is sued for claims that come within the coverage of the insurance policy.\nOriginally, individual companies that faced a common peril formed a group and created a self-help fund out of which to pay compensation should any member incur loss (in other words, a mutual insurance arrangement).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Brewers'_Distributor">Brewers' Distributor</a></td>
      <td>Brewers' Distributor Ltd. (BDL) is a Canadian company that distributes beer throughout the four western provinces and three northern territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/General_Film_Distributors">General Film Distributors</a></td>
      <td>General Film Distributors (GFD), later known as J. Arthur Rank Film Distributors and Rank Film Distributors Ltd., was a British film distribution company based in London. It was active between 1935 and 1996, and from 1937 it was part of the Rank Organisation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_film_distributors_by_country">List of film distributors by country</a></td>
      <td>This is a list of motion picture distributors, past and present, sorted alphabetically by country.\n\n\n== Albania ==\nConstantin Film\nUnited International Pictures\n\n\n== Argentina ==\nBuena Vista International\nWarner Bros.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sony_Pictures_Motion_Picture_Group">Sony Pictures Motion Picture Group</a></td>
      <td>Sony Pictures Entertainment Motion Picture Group (commonly known as Sony Pictures Motion Picture Group, formerly known as the Columbia TriStar Motion Picture Group until 2013, and abbreviated as SPMPG) is a division of Sony Pictures Entertainment to manage its motion picture operations. It was launched in 1998 by integrating the businesses of Columbia Pictures Industries, Inc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Titan_Distributors">Titan Distributors</a></td>
      <td>Titan Distributors was a British comic book distributor which existed from 1978 to 1993, when it was acquired by a larger U.S. distributor. Operated by Nick Landau, Mike Lake, and Mike Luckman, Titan Distributors supplied comics, science fiction, and other genre products to retailers all over the United Kingdom.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>WRIGHT MEDICAL GROUP INC      Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>Our business and its <font color="blue"><font color="blue">future performance</font> may</font> be <font color="blue">affected by various factors</font>,     the <font color="blue">most <font color="blue">significant</font></font> of which are discussed below</td>
    </tr>
    <tr>
      <td>We  are subject to substantial <font color="blue">government regulation</font> that could have a     material adverse effect on our business     The production and marketing of our products and our <font color="blue">ongoing research</font> and     development, preclinical testing and <font color="blue">clinical trial activities</font> are subject     to extensive regulation and <font color="blue">review by numerous <font color="blue"><font color="blue">governmental</font> authorities</font> both</font>     <font color="blue">in the US </font>and abroad</td>
    </tr>
    <tr>
      <td>US and foreign <font color="blue">regulations</font> govern the testing,     marketing and <font color="blue">registration</font> of new <font color="blue">medical devices</font>, in addition to regulating     <font color="blue">manufacturing</font> practices, reporting, labeling and <font color="blue">recordkeeping</font> procedures</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">regulatory</font> process</font> requires <font color="blue">significant</font> time, effort and <font color="blue">expenditures</font> to     bring our products to market, and we cannot be assured that any of our     <font color="blue">products will</font> be approved</td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue"><font color="blue">comply with</font> applicable <font color="blue">regulatory</font></font>     <font color="blue"><font color="blue">requirement</font>s could</font> result in these <font color="blue"><font color="blue">governmental</font> authorities</font>:     •   <font color="blue">imposing fines</font> and <font color="blue">penalties on us</font>;       •   preventing us from <font color="blue">manufacturing</font> or selling our products;       •   <font color="blue">bringing civil</font> or <font color="blue">criminal charges against us</font>;       •   delaying the <font color="blue">introduction</font> of our <font color="blue"><font color="blue">new products</font> into</font> the market;       •   recalling or seizing our products; or       •   withdrawing or <font color="blue">denying approvals</font> or <font color="blue">clearances</font> for our products</td>
    </tr>
    <tr>
      <td>Even if <font color="blue"><font color="blue">regulatory</font> approval</font> or clearance of a product is granted, this could     result in <font color="blue">limitations on</font> the uses for which the <font color="blue">product may</font> be labeled and     promoted</td>
    </tr>
    <tr>
      <td>Further,  for  a  marketed  product,  its  <font color="blue"><font color="blue">manufacture</font>r</font> and     <font color="blue">manufacturing</font> <font color="blue">facilities</font> are subject to periodic review and inspection</td>
    </tr>
    <tr>
      <td><font color="blue">Subsequent </font><font color="blue">discovery</font> of <font color="blue">problems with</font> a product, <font color="blue"><font color="blue">manufacture</font>r</font> or <font color="blue">facility</font>     may  result  in <font color="blue">restrictions on</font> the product, <font color="blue"><font color="blue">manufacture</font>r</font> or <font color="blue">facility</font>,     including withdrawal of the <font color="blue">product from</font> the market or other <font color="blue">enforcement</font>     actions</td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently conducting clinical studies</font> of some of our <font color="blue">products under</font>     an  IDE  Clinical  studies  must  be conducted in <font color="blue">compliance with</font> FDA     <font color="blue">regulations</font>, or the FDA may take <font color="blue">enforcement</font> action</td>
    </tr>
    <tr>
      <td>The <font color="blue">data collected from</font>     these <font color="blue">clinical studies will ultimately</font> be used to <font color="blue">support <font color="blue">market clearance</font></font>     for these products</td>
    </tr>
    <tr>
      <td>There is no assurance that the FDA will accept the data     from  these  clinical  studies or that it <font color="blue">will ultimately allow market</font>     clearance for these products</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">various federal</font> and state laws concerning health care     fraud  and abuse, including false claims laws, anti-kickback laws, and     physician  self-referral  laws</td>
    </tr>
    <tr>
      <td><font color="blue">Violations </font>of these laws can result in     criminal and/or civil punishment, including fines, <font color="blue">imprisonment</font>, and in the     US, <font color="blue">exclusion from <font color="blue">participation</font></font> in <font color="blue">government health care programs</font></td>
    </tr>
    <tr>
      <td>The     scope  of  these  laws and related <font color="blue">regulations</font> are expanding and their     <font color="blue">interpretation</font> is evolving</td>
    </tr>
    <tr>
      <td>There is very little precedent related to these     laws and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Increased </font>funding for <font color="blue">enforcement</font> of these laws and     <font color="blue">regulations</font> has resulted in <font color="blue">greater scrutiny</font> of <font color="blue">marketing practices</font> in our     industry  and resulted in <font color="blue">several government investigations by various</font>     <font color="blue">government authorities</font></td>
    </tr>
    <tr>
      <td>If a <font color="blue">governmental</font> authority were to determine that     we do not <font color="blue">comply with</font> these laws and <font color="blue">regulations</font>, then we and our officers     and employees could be subject to criminal and civil sanctions, including     <font color="blue">exclusion from <font color="blue">participation</font></font> in federal health care <font color="blue">reimbursement</font> programs</td>
    </tr>
    <tr>
      <td>In  order to market our <font color="blue">product devices</font> in the member countries of the     European Union (EU), we are required to <font color="blue">comply with</font> the Medical Devices     Directive and obtain CE mark <font color="blue">certification</font></td>
    </tr>
    <tr>
      <td>CE mark <font color="blue">certification</font> is the     European symbol of adherence to <font color="blue">quality assurance standards</font> and compliance     with  applicable <font color="blue">European Medical Device Directives</font></td>
    </tr>
    <tr>
      <td>Under the Medical     Devices  Directive, all <font color="blue">medical devices</font> including <font color="blue">active implants must</font>     qualify for CE marking</td>
    </tr>
    <tr>
      <td>In August 2005, an <font color="blue">EU Medical Devices Directive     </font>changed the classification of hip, knee, and <font color="blue">shoulder implants from</font> class     IIb  to  class  III  The  transition  period for these changes begins     <font color="blue">September </font>1, 2007</td>
    </tr>
    <tr>
      <td>Upon <font color="blue">reclassification</font> to class III, <font color="blue"><font color="blue">manufacture</font>r</font>s will be     required to assemble <font color="blue">significant</font>ly more <font color="blue">documentation</font> and submit it to their     <font color="blue">Notified Body </font>for formal approval prior to affixing the CE mark to their     product  and  packaging</td>
    </tr>
    <tr>
      <td>We intend to <font color="blue">comply with</font> the Medical Devices     Directive for all of our products <font color="blue"><font color="blue">manufacture</font>d</font> and sold in the EU However,     there can be no assurance that our <font color="blue">products will</font> be approved for CE marking     in a <font color="blue">timely manner</font> or at all</td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________    [41]Table of <font color="blue">Contents       </font>Our biologics business is subject to emerging <font color="blue">governmental</font> <font color="blue">regulations</font> that     can <font color="blue">significant</font>ly impact our business     The  FDA has <font color="blue">statutory authority</font> to regulate allograft-based products,     processing and materials</td>
    </tr>
    <tr>
      <td>The FDA has been working to establish a more     <font color="blue">comprehensive <font color="blue">regulatory</font> framework</font> for allograft-based products, which are     <font color="blue">principally <font color="blue">derived from</font> cadaveric tissue</font></td>
    </tr>
    <tr>
      <td>The framework developed by the     FDA  <font color="blue">establishes</font>  criteria  for determining whether a <font color="blue">particular human</font>     tissue-based product will be <font color="blue">classified as <font color="blue">human tissue</font></font>, a medical device or     <font color="blue">biologic drug</font> requiring <font color="blue">pre<font color="blue">market clearance</font></font> or approval</td>
    </tr>
    <tr>
      <td>All tissue-based     products are subject to extensive FDA regulation, including a <font color="blue">requirement</font>     that ensures that diseases are not transmitted to <font color="blue">tissue recipients</font></td>
    </tr>
    <tr>
      <td><font color="blue">The FDA     </font>has <font color="blue">also proposed</font> extensive <font color="blue">additional</font> <font color="blue">regulations</font> that <font color="blue">would govern</font> the     processing and <font color="blue">distribution</font> of all <font color="blue">allograft products</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">regulations</font> for allograft-based     products are still developing</td>
    </tr>
    <tr>
      <td>From time to time, the FDA reviews these     products and <font color="blue">may informally</font> suggest to us how these <font color="blue">products should</font> be     classified</td>
    </tr>
    <tr>
      <td>If it is     considered a medical device or <font color="blue">biologic drug</font>, then FDA clearance or approval     may be required</td>
    </tr>
    <tr>
      <td>Additionally,  our  biologics  business  involves  the <font color="blue">procurement</font> and     <font color="blue">transplantation</font> of allograft tissue, which is subject to <font color="blue">federal regulation</font>     under <font color="blue">NOTA NOTA </font>prohibits the sale of <font color="blue">human organs</font>, including bone and     other <font color="blue">human tissue</font>, for valuable <font color="blue">consideration within</font> the meaning of NOTA     NOTA  permits  the  payment of <font color="blue">reasonable expenses associated with</font> the     transportation, processing, preservation, quality control and storage of     <font color="blue">human tissue</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">currently charge</font> our customers for these expenses</td>
    </tr>
    <tr>
      <td>In the     future, if NOTA is amended or <font color="blue">reinterpreted</font>, we may not be able to charge     these expenses to our customers and, as a result, our business could be     <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td><font color="blue">Modifications </font>to our marketed devices may require FDA <font color="blue">regulatory</font> <font color="blue">clearances</font>     or approvals or require us to <font color="blue">cease marketing</font> or recall the <font color="blue">modified devices</font>     until such <font color="blue">clearances</font> or approvals are obtained     When required, the products we market <font color="blue">in the US </font>have obtained premarket     <font color="blue">notification under</font> Section 510(k) of the FDC Act or were exempt from the     510(k) clearance process</td>
    </tr>
    <tr>
      <td>We have modified some of our products and product     <font color="blue">labeling since</font> obtaining 510(k) clearance, but we do not believe these     <font color="blue">modifications</font> require us to submit new 510(k) notifications</td>
    </tr>
    <tr>
      <td>However, if the     FDA <font color="blue">disagrees with us</font> and requires us to submit a new 510(k) notification     for  <font color="blue">modifications</font>  to our <font color="blue">existing products</font>, we may be the subject of     <font color="blue">enforcement</font>  actions  by the FDA and be required to stop marketing the     products while the FDA reviews the 510(k) notification</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>requires     us  to  go  through a lengthier, more <font color="blue">rigorous examination than</font> we had     expected, our product <font color="blue">introduction</font>s or <font color="blue">modifications</font> could be delayed or     canceled, <font color="blue">which could</font> cause our sales to decline</td>
    </tr>
    <tr>
      <td>In addition, the FDA may     determine that future <font color="blue">products will</font> require the more costly, lengthy and     uncertain PMA <font color="blue"><font color="blue">application</font> process</font></td>
    </tr>
    <tr>
      <td>Products that are <font color="blue">approved through</font> a PMA     <font color="blue"><font color="blue">application</font> generally</font> need FDA approval before they can be modified</td>
    </tr>
    <tr>
      <td>”     If we lose one of our <font color="blue">key suppliers</font>, we may be unable to <font color="blue">meet customer</font>     orders for our products in a <font color="blue">timely manner</font> or within our budget     We rely on a limited number of suppliers for the <font color="blue"><font color="blue">components</font> used</font> in our     products</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">reconstructive joint devices</font> are produced <font color="blue">from various</font>     <font color="blue">surgical grades</font> of titanium, cobalt chrome and stainless steel, various     grades of high-density polyethylenes, <font color="blue">silicone elastomer</font> and ceramics</td>
    </tr>
    <tr>
      <td>We     rely  <font color="blue">on one supplier</font> for the <font color="blue"><font color="blue">silicone elastomer</font> used</font> in our extremity     products</td>
    </tr>
    <tr>
      <td>We are aware of <font color="blue">only two suppliers</font> of <font color="blue">silicone elastomer</font> to the     medical device industry for <font color="blue">permanent implant usage</font></td>
    </tr>
    <tr>
      <td>Additionally, we rely     <font color="blue">on one supplier</font> of ceramics for use in our <font color="blue">hip products</font></td>
    </tr>
    <tr>
      <td>In addition, for our <font color="blue">biologics products</font>, we <font color="blue">presently depend upon</font> a single     <font color="blue">supplier as</font> our source for DBM and CBM, and any failure to obtain DBM and     CBM from this source in a <font color="blue">timely manner</font> will deplete levels of on-hand raw     <font color="blue">materials inventory</font> and <font color="blue">could interfere with</font> our ability to process and     distribute  <font color="blue">allograft products</font></td>
    </tr>
    <tr>
      <td>During 2006, we are expecting a single     not-for-profit tissue bank to <font color="blue">meet nearly</font> all of our <font color="blue">DBM and CBM </font>order     <font color="blue">requirement</font>s,  a  key component in the <font color="blue">allograft products</font> we currently     produce, market and distribute</td>
    </tr>
    <tr>
      <td>We cannot be sure that our supply of DBM and     CBM will continue to be <font color="blue">available at <font color="blue">current levels</font></font> or will be sufficient to     meet our needs, or that future                                         15       _________________________________________________________________    [42]Table of <font color="blue">Contents       </font>suppliers of <font color="blue">DBM and CBM </font>will be free from FDA <font color="blue"><font color="blue">regulatory</font> action impacting</font>     their sale of <font color="blue">DBM and CBM </font>Since there is a small number of suppliers, if we     <font color="blue">cannot continue</font> to obtain <font color="blue">DBM and CBM </font>from our <font color="blue">current source</font> in volumes     sufficient to meet our needs, we may not be able to <font color="blue">locate replacement</font>     sources of <font color="blue">DBM and CBM </font><font color="blue">on commercially reasonable terms</font>, if at all</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>could have the effect of <font color="blue">interrupting</font> our business, <font color="blue"><font color="blue">which could</font> <font color="blue">adversely</font></font>     affect our sales</td>
    </tr>
    <tr>
      <td>Further, we rely <font color="blue">on one supplier</font> for our GRAFTJACKET^^®     family of <font color="blue">soft tissue repair</font> and graft containment products, as well as one     supplier for our ADCON^^® Gel products</td>
    </tr>
    <tr>
      <td><font color="blue">Suppliers </font>of <font color="blue">raw materials</font> and <font color="blue">components</font> may decide, or be required, for     reasons beyond our control to cease supplying <font color="blue">raw materials</font> and <font color="blue">components</font>     to us</td>
    </tr>
    <tr>
      <td>FDA <font color="blue">regulations</font> may require <font color="blue"><font color="blue">additional</font> testing</font> of any <font color="blue">raw materials</font>     or <font color="blue">components</font> from new suppliers prior to our use of these materials or     <font color="blue">components</font> and in the case of a device with a PMA <font color="blue">application</font>, we may be     required to obtain prior FDA permission, either of <font color="blue"><font color="blue">which could</font> delay</font> or     prevent our access to or use of such <font color="blue">raw materials</font> or <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">compete <font color="blue">successfully</font></font> in the <font color="blue">future against</font> our existing or     <font color="blue">potential <font color="blue">competitors</font></font>, our sales and operating results may be <font color="blue">negatively</font>     affected and we may not achieve <font color="blue">future growth</font>     The markets for our products are <font color="blue">highly competitive</font> and <font color="blue">dominated by</font> a small     number of large companies</td>
    </tr>
    <tr>
      <td>We may not be able to meet the <font color="blue">prices <font color="blue">offered by</font></font>     our <font color="blue">competitors</font>, or <font color="blue">offer products</font> similar to or more <font color="blue">desirable than</font> those     <font color="blue">offered by</font> our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>”     If  we  are  unable to continue to develop and <font color="blue">market <font color="blue">new products</font></font> and     <font color="blue">technologies</font>, we may experience a decrease in demand for our products or our     <font color="blue">products could become obsolete</font>, and our business <font color="blue">would suffer</font>     We are <font color="blue">continually</font> engaged in <font color="blue">product development</font> and <font color="blue">improvement programs</font>,     and <font color="blue"><font color="blue">new products</font> represent</font> a <font color="blue">significant</font> component of our <font color="blue">growth rate</font></td>
    </tr>
    <tr>
      <td>We     may be unable to <font color="blue">compete <font color="blue">effective</font>ly with</font> our <font color="blue">competitors</font> unless we can keep     <font color="blue">up with existing</font> or <font color="blue">new products</font> and <font color="blue">technologies</font> in the <font color="blue">orthopaedic implant</font>     market</td>
    </tr>
    <tr>
      <td>If we do not continue to introduce <font color="blue">new products</font> and <font color="blue">technologies</font>, or     if  those  products  and  <font color="blue">technologies</font> are not accepted, we may not be     successful</td>
    </tr>
    <tr>
      <td>Additionally, our <font color="blue">competitors</font>’ <font color="blue">new products</font> and <font color="blue">technologies</font> may     beat our products to market, may be more <font color="blue">effective</font> or <font color="blue">less expensive than</font>     our  products,  or  may  render our <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>”     If our patents and other <font color="blue">intellectual property</font> rights do not <font color="blue">adequately</font>     protect our products, we <font color="blue">may lose market</font> share to our <font color="blue">competitors</font> and be     unable to operate our business profitably     We rely on patents, <font color="blue">trade secrets</font>, copyrights, know-how, trademarks, license     <font color="blue">agreements</font> and <font color="blue">contractual provisions</font> to establish our <font color="blue">intellectual property</font>     rights and protect our products</td>
    </tr>
    <tr>
      <td>”     These legal means, however, afford only limited protection and may not     <font color="blue">adequately</font> protect our rights</td>
    </tr>
    <tr>
      <td>In addition, we cannot be assured that any of     our pending patent <font color="blue">application</font>s will issue</td>
    </tr>
    <tr>
      <td><font color="blue">The USPTO </font>may deny or require a     <font color="blue">significant</font> narrowing of the claims in our pending patent <font color="blue">application</font>s and     the <font color="blue">patents issuing from</font> such <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>Any <font color="blue">patents issuing from</font> the     pending patent <font color="blue">application</font>s may not provide us with <font color="blue">significant</font> commercial     protection</td>
    </tr>
    <tr>
      <td>We <font color="blue">could incur</font> substantial costs in <font color="blue">proceedings</font> before the     USPTO  These  <font color="blue">proceedings</font> could result in <font color="blue">adverse decisions as</font> to the     priority of our <font color="blue">inventions</font> and the narrowing or <font color="blue">invalidation</font> of claims in     <font color="blue">issued patents</font></td>
    </tr>
    <tr>
      <td>In addition, the laws of some of the countries in which our     products are or may be sold may not protect our <font color="blue">intellectual property</font> to the     <font color="blue">same extent as</font> US laws or at all</td>
    </tr>
    <tr>
      <td>We also may be unable to protect our     rights in <font color="blue">trade secrets</font> and <font color="blue">unpatented <font color="blue">proprietary technology</font></font> in these     countries</td>
    </tr>
    <tr>
      <td>In addition, we hold <font color="blue">licenses from third parties</font> that are <font color="blue">necessary</font> to     utilize certain <font color="blue">technologies</font> used in the design and <font color="blue">manufacturing</font> of some of     our products</td>
    </tr>
    <tr>
      <td>The loss of such licenses would <font color="blue">prevent us from</font> <font color="blue">manufacturing</font>,     marketing and selling these products, <font color="blue">which could</font> harm our business</td>
    </tr>
    <tr>
      <td>We  seek  to  protect our <font color="blue">trade secrets</font>, know-how and other unpatented     <font color="blue">proprietary technology</font>, in part, with confidentiality <font color="blue">agreements</font> with our     employees, independent <font color="blue">distributors</font> and <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>We cannot be assured,     however, that the <font color="blue">agreements</font> will not be breached, adequate remedies for any     breach  would  be available, or our <font color="blue">trade secrets</font>, know-how, and other     <font color="blue">unpatented <font color="blue">proprietary technology</font></font> will not <font color="blue">otherwise become known</font> to or     <font color="blue">independently</font> developed by our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>16       _________________________________________________________________    [43]Table of <font color="blue">Contents       </font>If we lose any existing or future <font color="blue">intellectual property</font> lawsuits, a court     could require us to pay <font color="blue">significant</font> damages or <font color="blue"><font color="blue">prevent us from</font> selling</font> our     products     The medical device industry is <font color="blue">litigious with respect</font> to patents and other     <font color="blue">intellectual property</font> rights</td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>in the medical device industry have     used <font color="blue">intellectual property</font> <font color="blue">litigation</font> to gain a <font color="blue">competitive advantage</font></td>
    </tr>
    <tr>
      <td>We     are <font color="blue">currently involved</font> in an <font color="blue">intellectual property</font> lawsuit with Howmedica     Osteonics Corp, a subsidiary of Stryker Corporation, where it is alleged     that our ADVANCE^^® Knee <font color="blue">product line infringes one</font> of Howmedica’s patents</td>
    </tr>
    <tr>
      <td>See “Legal Proceedings” for more information regarding this lawsuit</td>
    </tr>
    <tr>
      <td>If     Howmedica were to succeed in obtaining the relief it claims, the <font color="blue">court could</font>     <font color="blue">award damages</font> to Howmedica and impose an injunction against further sales of     our product</td>
    </tr>
    <tr>
      <td>If a monetary judgment is rendered against us, we may be forced     to raise or borrow funds, as a supplement to any <font color="blue">available insurance</font> claim     proceeds, to pay the <font color="blue">damages award</font></td>
    </tr>
    <tr>
      <td>In the future, we may become a party to other <font color="blue">lawsuits involving patents</font> or     other <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>A legal proceeding, regardless of the outcome,     <font color="blue">could drain</font> our <font color="blue">financial resources</font> and divert the time and effort of our     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>If we lose one of these <font color="blue">proceedings</font>, a court, or a similar     <font color="blue">foreign governing</font> body, could require us to pay <font color="blue">significant</font> damages to third     parties, require us to seek <font color="blue">licenses from third parties</font> and pay ongoing     royalties,  require  us  to  redesign our products, or <font color="blue">prevent us from</font>     <font color="blue">manufacturing</font>, using or selling our products</td>
    </tr>
    <tr>
      <td>In addition to being costly,     <font color="blue">protracted <font color="blue">litigation</font></font> to defend or prosecute our <font color="blue">intellectual property</font>     <font color="blue">rights could</font> result in our customers or <font color="blue">potential customers deferring</font> or     limiting their purchase or use of the <font color="blue">affected products until resolution</font> of     the <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">product <font color="blue">liability</font></font> lawsuits are <font color="blue">brought against us</font>, our business may be     harmed     The <font color="blue">manufacture</font> and sale of <font color="blue">medical devices</font> exposes us to <font color="blue">significant</font> risk     of <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>In the past, we have had a number of product     <font color="blue">liability</font>  claims  relating  to  our  products,  none  of which either     <font color="blue">individually</font>, or in the aggregate, have resulted in a material negative     <font color="blue">impact on</font> our business</td>
    </tr>
    <tr>
      <td>In the future, we may be subject to <font color="blue">additional</font>     <font color="blue">product <font color="blue">liability</font></font> claims, some of which may have a negative <font color="blue">impact on</font> our     business</td>
    </tr>
    <tr>
      <td>Additionally,  we  could  experience  a  material design or     <font color="blue">manufacturing</font> failure in our products, a <font color="blue">quality system failure</font>, other     <font color="blue">safety issues</font>, or <font color="blue">heightened <font color="blue">regulatory</font> scrutiny</font> that <font color="blue">would warrant</font> a recall     of some of our products</td>
    </tr>
    <tr>
      <td>Our existing <font color="blue">product <font color="blue">liability</font></font> <font color="blue">insurance coverage</font>     may be inadequate to <font color="blue">protect us from</font> any <font color="blue">liabilities</font> we <font color="blue">might incur</font></td>
    </tr>
    <tr>
      <td>If a     product  <font color="blue">liability</font> claim or series of claims is <font color="blue">brought against us</font> for     uninsured <font color="blue">liabilities</font> or in excess of our <font color="blue">insurance coverage</font>, our business     <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>In addition, a recall of some of our products, whether or not     the result of a <font color="blue">product <font color="blue">liability</font></font> claim, could result in <font color="blue">significant</font> costs     and loss of customers</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in insurance expense could <font color="blue">adversely</font> affect our <font color="blue">profitability</font>     We  hold  a  number of <font color="blue">insurance policies</font>, including <font color="blue">product <font color="blue">liability</font></font>     insurance, directors’ and officers’ <font color="blue">liability</font> insurance, property insurance     and workers’ compensation insurance</td>
    </tr>
    <tr>
      <td>If the costs of maintaining adequate     insurance  coverage  should  increase <font color="blue">significant</font>ly in the future, our     operating results could be materially <font color="blue">adversely</font> impacted</td>
    </tr>
    <tr>
      <td>If we cannot retain our <font color="blue">key personnel</font>, we will not be able to manage and     operate <font color="blue">successfully</font> and we may not be able to meet our <font color="blue">strategic objectives</font>     Our continued success depends, in part, upon key managerial, scientific,     sales and technical personnel, as well as our ability to continue to attract     and  retain <font color="blue">additional</font> highly <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>We compete for such     <font color="blue">personnel with</font> other companies, academic institutions, <font color="blue">governmental</font> entities     and  other  <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>There  can be no assurance that we will be     successful in retaining our <font color="blue">current personnel</font> or in hiring or retaining     <font color="blue">qualified personnel</font> in the future</td>
    </tr>
    <tr>
      <td>Loss of <font color="blue">key personnel</font> or the <font color="blue">inability</font> to     hire or retain <font color="blue">qualified personnel</font> in the <font color="blue">future could</font> have a material     adverse  effect  on  our ability to operate <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>Further, any     <font color="blue">inability</font> on our part to enforce non-compete <font color="blue">arrangements</font> related to key     personnel who have left the business could have a material adverse effect on     our business</td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________    [44]Table of <font color="blue">Contents       </font>We  derive  a  <font color="blue">significant</font>  portion  of  our  <font color="blue">sales from <font color="blue">operations</font></font> in     <font color="blue"><font color="blue">international</font> markets</font> that are subject to political, economic and social     <font color="blue">instability</font>     We  derive  a  <font color="blue">significant</font>  portion  of  our  <font color="blue">sales from <font color="blue">operations</font></font> in     <font color="blue"><font color="blue">international</font> markets</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font> <font color="blue">distribution</font> system consists of 8     <font color="blue">direct sales offices</font> and <font color="blue">approximately</font> 100 stocking <font color="blue">distribution</font> partners,     which combined employ <font color="blue">approximately</font> 430 <font color="blue">sales representatives</font> who sell in     over 60 countries</td>
    </tr>
    <tr>
      <td>Most of these countries are, to some degree, subject to     political, social and economic <font color="blue">instability</font></td>
    </tr>
    <tr>
      <td>For the years ended <font color="blue">December </font>31,     2005 and 2004, <font color="blue">approximately</font> 38prca and 39prca, respectively, of our net sales     were <font color="blue">derived from</font> our <font color="blue"><font color="blue">international</font> <font color="blue">operations</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">international</font> sales</font>     <font color="blue"><font color="blue">operations</font> expose us</font> and our representatives, agents and <font color="blue">distributors</font> to     <font color="blue">risks inherent</font> in operating in <font color="blue">foreign jurisdictions</font></td>
    </tr>
    <tr>
      <td>These risks include:     •   the imposition of <font color="blue">additional</font> foreign <font color="blue">governmental</font> controls or     <font color="blue">regulations</font> on <font color="blue">orthopaedic implant</font>s and <font color="blue">biologics products</font>;     •   new export license <font color="blue">requirement</font>s, particularly related to our biologics     products;     •   economic <font color="blue">instability</font>, including <font color="blue">currency risk between</font> the US dollar     and <font color="blue">foreign currencies</font>, in our <font color="blue">target markets</font>;     •   a shortage of high-quality <font color="blue"><font color="blue">international</font> sales</font>people and <font color="blue">distributors</font>;     •   loss of any <font color="blue">key personnel</font> who possess <font color="blue">proprietary knowledge</font> or are     otherwise important to our success in <font color="blue"><font color="blue">international</font> markets</font>;     •   changes in third-party <font color="blue">reimbursement</font> policy that may require some of the     patients who receive our <font color="blue">implant products</font> to <font color="blue">directly absorb medical costs</font>     or that <font color="blue">may necessitate</font> our <font color="blue">reducing selling prices</font> for our products;     •   changes in tariffs and other trade restrictions, particularly related to     the <font color="blue">exportation</font> of our <font color="blue">biologics products</font>;     •   work stoppages or strikes in the <font color="blue">health care industry</font>, such as those     that have <font color="blue"><font color="blue">previously</font> affected</font> our <font color="blue">operations</font> in France, Canada, Korea and     Finland in the past;     •   a shortage of nurses in some of our <font color="blue">target markets</font>, particularly     <font color="blue">affecting</font> our <font color="blue">operations</font> in France; and     •   exposure to <font color="blue">different</font> legal and political standards due to our     conducting business in over 60 countries</td>
    </tr>
    <tr>
      <td>Any material decrease in our foreign sales would <font color="blue">negatively</font> impact our     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">international</font> sales</font> are <font color="blue">predominately generated</font> in     Europe</td>
    </tr>
    <tr>
      <td>In Europe, <font color="blue">health care regulation</font> and <font color="blue">reimbursement</font> for medical     devices  vary  <font color="blue">significant</font>ly  from  country  to country</td>
    </tr>
    <tr>
      <td>This changing     environment could <font color="blue">adversely</font> affect our ability to sell our products in some     European countries</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">could suffer</font> if the <font color="blue">medical <font color="blue">community</font></font> does not continue to     <font color="blue">accept allograft technology</font>     New <font color="blue">allograft products</font>, <font color="blue">technologies</font> and <font color="blue">enhancements may never</font> achieve     <font color="blue">broad market <font color="blue">acceptance</font> due</font> to <font color="blue">numerous factors</font>, including:     •   lack of <font color="blue">clinical <font color="blue">acceptance</font></font> of <font color="blue">allograft products</font> and related     <font color="blue">technologies</font>;     •   the <font color="blue">introduction</font> of <font color="blue">competitive tissue repair treatment options</font> that     render <font color="blue">allograft products</font> and <font color="blue">technologies</font> too expensive and obsolete;     •   lack of available third-party <font color="blue">reimbursement</font>;     •   the <font color="blue">inability</font> to <font color="blue">train surgeons</font> in the use of <font color="blue">allograft products</font> and     <font color="blue">technologies</font>;     •   the risk of <font color="blue">disease transmission</font>; and     •   <font color="blue">ethical concerns about</font> the <font color="blue">commercial aspects</font> of <font color="blue">harvesting cadaveric</font>     tissue</td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________    [45]Table of <font color="blue">Contents       </font>Market  <font color="blue"><font color="blue">acceptance</font> will also depend on</font> the ability to <font color="blue">demonstrate</font> that     existing and <font color="blue">new <font color="blue">allografts</font></font> and <font color="blue">technologies</font> are <font color="blue">attractive alternatives</font> to     <font color="blue">existing tissue repair treatment options</font></td>
    </tr>
    <tr>
      <td>To <font color="blue">demonstrate</font> this, we rely upon     surgeon  <font color="blue">evaluations</font>  of  the  clinical safety, efficacy, ease of use,     re<font color="blue">liability</font>  and  cost  <font color="blue">effective</font>ness of our <font color="blue">tissue repair options</font> and     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Recommendations </font>and <font color="blue">endorsements</font> by <font color="blue">influential</font> surgeons are     important to the <font color="blue">commercial success</font> of <font color="blue">allograft products</font> and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>In  addition,  several  countries,  notably Japan, prohibit the use of     <font color="blue">allografts</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">allograft products</font> and <font color="blue">technologies</font> are not <font color="blue">broadly accepted</font>     in the marketplace, we may not achieve a <font color="blue">competitive position</font> in the market</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate levels</font> of <font color="blue">reimbursement</font> from third-party payors for our products     are not obtained, surgeons and <font color="blue">patients may</font> be reluctant to use our products     and our <font color="blue">sales may decline</font>     In the US, <font color="blue">health <font color="blue">care providers</font></font> that purchase our <font color="blue">products generally rely</font>     on third-party payors, principally federal Medicare, state Medicaid and     <font color="blue">private health</font> insurance plans, to pay for all or a portion of the cost of     <font color="blue">joint reconstructive procedures</font> and <font color="blue">products utilized</font> in those procedures</td>
    </tr>
    <tr>
      <td>We may be unable to sell our <font color="blue">products on</font> a <font color="blue">profitable basis</font> if third-party     <font color="blue">payors <font color="blue">deny coverage</font></font> or reduce their <font color="blue">current levels</font> of <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>Our     sales depend largely on <font color="blue">governmental</font> health care programs and <font color="blue">private health</font>     insurers reimbursing patients’ medical expenses</td>
    </tr>
    <tr>
      <td>Surgeons, hospitals and     other <font color="blue"><font color="blue">health <font color="blue">care providers</font></font> may</font> not purchase our products if they do not     receive satisfactory <font color="blue">reimbursement</font> from these third-party payors for the     cost of the <font color="blue">procedures using</font> our products</td>
    </tr>
    <tr>
      <td>Payors continue to review their     <font color="blue">coverage policies carefully</font> for existing and <font color="blue">new therapies</font> and can, without     notice, <font color="blue">deny coverage</font> for <font color="blue">treatments</font> that include the use of our products</td>
    </tr>
    <tr>
      <td>In addition, some <font color="blue">health <font color="blue">care providers</font></font> <font color="blue">in the US </font>have adopted or are     considering a <font color="blue">managed care system</font> in which the <font color="blue">providers contract</font> to provide     <font color="blue">comprehensive heath care</font> for a fixed cost per person</td>
    </tr>
    <tr>
      <td>Health <font color="blue">care providers</font>     may  attempt  to  <font color="blue">control costs by authorizing fewer elective surgical</font>     procedures, including <font color="blue">joint reconstructive surgeries</font>, or by requiring the     use of the <font color="blue">least expensive implant available</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate levels</font> of <font color="blue">reimbursement</font> from third-party payors outside of the     US are not obtained, <font color="blue"><font color="blue">international</font> sales</font> of our <font color="blue">products may decline</font></td>
    </tr>
    <tr>
      <td>Outside of the US, <font color="blue">reimbursement</font> systems vary <font color="blue">significant</font>ly by country</td>
    </tr>
    <tr>
      <td>Many foreign markets have government-managed health care systems that govern     <font color="blue">reimbursement</font> for <font color="blue">medical devices</font> and procedures</td>
    </tr>
    <tr>
      <td>Canada, and some European     and Asian countries, in particular France, Japan, Taiwan, and Korea, have     tightened <font color="blue">reimbursement</font> rates</td>
    </tr>
    <tr>
      <td>Additionally, some foreign <font color="blue">reimbursement</font>     <font color="blue">systems provide</font> for limited payments in a <font color="blue">given period</font> and therefore result     in <font color="blue">extended payment periods</font></td>
    </tr>
    <tr>
      <td>See “Business – Third-Party Reimbursement” for     more information regarding <font color="blue">reimbursement</font> <font color="blue">in the US </font>and abroad</td>
    </tr>
    <tr>
      <td>If <font color="blue">market clearance</font> is not obtained for the re-launch of the ADCON ^® Gel     products and the launch of the CONSERVE^® Plus implant in the US, growth     of our biologics and <font color="blue">hip <font color="blue">product lines</font> could</font> be impacted     Our ADCON^^® Gel products and our CONSERVE^^® Plus Resurfacing Implant are     <font color="blue">available outside</font> the US There can be no assurance that the sale of our     ADCON^^® Gel or CONSERVE^^® Plus products <font color="blue">in the US </font>will be <font color="blue">cleared by</font> the     FDA in a <font color="blue">timely manner</font> or at all, <font color="blue">which could</font> have a <font color="blue">significant</font> <font color="blue">impact on</font>     the <font color="blue">future growth</font> of our biologics and hip <font color="blue">product lines</font>, respectively</td>
    </tr>
    <tr>
      <td>In 2005, our PMA <font color="blue">application</font> with the FDA for our ADCON^^® Gel product was     withdrawn by <font color="blue">management</font></td>
    </tr>
    <tr>
      <td><font color="blue">Management </font>is <font color="blue">evaluating whether</font> to continue to     pursue re-submission for this product</td>
    </tr>
    <tr>
      <td>If re-submitted, there can be no     assurance that the FDA will accept another submission for filing in a timely     manner or at all</td>
    </tr>
    <tr>
      <td>If surgeons do not recommend and endorse our products, our <font color="blue">sales may decline</font>     or we may be unable to increase our sales and profits     In order for us to sell our products, surgeons must recommend and endorse     them</td>
    </tr>
    <tr>
      <td>We may not obtain the <font color="blue">necessary</font> recommendations or <font color="blue">endorsements</font> from     surgeons</td>
    </tr>
    <tr>
      <td><font color="blue">Acceptance </font>of our products depends on educating the medical     <font color="blue">community</font>  as  to the <font color="blue">distinctive characteristics</font>, perceived benefits,     clinical  efficacy  and cost-<font color="blue">effective</font>ness of our <font color="blue">products compared</font> to     products  of  our  <font color="blue">competitors</font>  and <font color="blue">on training surgeons</font> in the proper     <font color="blue">application</font> of our products</td>
    </tr>
    <tr>
      <td>19       _________________________________________________________________    [46]Table of <font color="blue">Contents       </font>If a natural or man-made disaster strikes our <font color="blue">manufacturing</font> <font color="blue">facilities</font>, we     could be unable to <font color="blue">manufacture</font> our products for a substantial amount of time     and our <font color="blue">sales could decline</font>     We  have <font color="blue">principally relied</font> to date on our <font color="blue">manufacturing</font> <font color="blue">facilities</font> in     Arlington,  Tennessee,  and  Toulon,  France</td>
    </tr>
    <tr>
      <td>These <font color="blue">facilities</font> and the     <font color="blue">manufacturing</font> equipment we use to produce our <font color="blue">products would</font> be <font color="blue">difficult</font> to     replace and could require substantial lead-time to repair or replace</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">facilities</font> may be <font color="blue">affected by natural</font> or man-made disasters</td>
    </tr>
    <tr>
      <td>In the event     one of our <font color="blue">facilities</font> was affected by a disaster, we would be forced to rely     on third-party <font color="blue"><font color="blue">manufacture</font>r</font>s or shift production to our other <font color="blue">manufacturing</font>     <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Although we believe we possess <font color="blue">adequate insurance</font> for damage to     our  property and the <font color="blue">disruption</font> of our business from casualties, such     <font color="blue">insurance may</font> not be sufficient to cover all of our <font color="blue">potential losses</font> and may     not continue to be available to us on acceptable terms or at all</td>
    </tr>
    <tr>
      <td>Our business plan <font color="blue">relies on certain <font color="blue">assumptions</font> about</font> the market for our     products, which, if incorrect, may <font color="blue">adversely</font> affect our <font color="blue">profitability</font>     We believe that the aging of the <font color="blue">general population</font> and <font color="blue">increasingly active</font>     <font color="blue">lifestyles will continue</font> and that these <font color="blue">trends will increase</font> the need for     our <font color="blue">orthopaedic implant</font> products</td>
    </tr>
    <tr>
      <td>The projected demand for our products     <font color="blue">could materially differ from actual demand</font> if our <font color="blue">assumptions</font> regarding     these trends and <font color="blue">acceptance</font> of our <font color="blue">products by</font> the <font color="blue">medical <font color="blue">community</font></font> prove     to be incorrect or do not <font color="blue">materialize</font>, or if non-surgical <font color="blue">treatments</font> gain     more widespread <font color="blue">acceptance</font> as a <font color="blue">viable alternative</font> to <font color="blue">orthopaedic implant</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in foreign currency exchange rates could result in declines in     our reported sales and earnings     Since  a  majority of our <font color="blue"><font color="blue">international</font> sales</font> are <font color="blue">denominated</font> in local     currencies and not in US dollars, our reported sales and earnings are     subject to <font color="blue">fluctuations</font> in <font color="blue">foreign exchange rates</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font> net     sales were <font color="blue">favorably affected by</font> the impact of foreign currency <font color="blue">fluctuations</font>     totaling  <font color="blue">approximately</font>  dlra400cmam000 in 2005 and dlra8dtta1 million in 2004</td>
    </tr>
    <tr>
      <td>We     <font color="blue">currently employ</font> a derivative program using 30-day foreign currency forward     contracts to mitigate the risk of currency <font color="blue">fluctuations</font> on our <font color="blue">intercompany</font>     receivable and <font color="blue">payable balances</font> that are <font color="blue">denominated</font> in <font color="blue">foreign currencies</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">forward contracts</font> are expected to offset the <font color="blue">transactional gains</font> and     losses on the related <font color="blue">intercompany</font> balances</td>
    </tr>
    <tr>
      <td>These <font color="blue">forward contracts</font> are not     designated  as  <font color="blue">hedging instruments under</font> SFAS Nodtta 133, <font color="blue">Accounting </font>for     <font color="blue">Derivative Instruments and Hedging Activities</font></td>
    </tr>
    <tr>
      <td>Accordingly, the changes in     the fair value and the settlement of the contracts are recognized in the     <font color="blue">period incurred</font></td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________    [47]Table of <font color="blue">Contents       </font>Efforts to acquire and integrate other companies or <font color="blue">product lines</font> could     <font color="blue">adversely</font> affect our <font color="blue">operations</font> and financial results     We <font color="blue">may pursue <font color="blue">acquisitions</font></font> of other companies or <font color="blue">product lines</font></td>
    </tr>
    <tr>
      <td>Our ability     to  grow  through  <font color="blue">acquisitions</font>  <font color="blue">depends upon</font> our ability to identify,     negotiate, complete and integrate suitable <font color="blue">acquisitions</font> and to obtain any     <font color="blue">necessary</font>  financing</td>
    </tr>
    <tr>
      <td>Even  if  we complete <font color="blue">acquisitions</font>, we may also     experience:     •   <font color="blue">difficult</font>ies in <font color="blue">integrating</font> any acquired companies, personnel and     products into our existing business;     •   delays in realizing the benefits of the acquired company or products;     •   diversion of our <font color="blue">management</font>’s time and <font color="blue">attention from</font> other business     concerns;     •   limited or <font color="blue">no direct prior</font> experience in <font color="blue">new markets</font> or countries we may     enter;     •   <font color="blue">higher costs</font> of <font color="blue">integration than</font> we anticipated; or     •   <font color="blue">difficult</font>ies in retaining <font color="blue">key employees</font> of the acquired business who are     <font color="blue">necessary</font> to manage these <font color="blue">acquisitions</font></td>
    </tr>
    <tr>
      <td>In addition, an <font color="blue">acquisition could materially impair</font> our operating results by     causing us to incur debt or requiring us to <font color="blue">amortize acquisition expenses</font>     and acquired assets</td>
    </tr>
    <tr>
      <td>Our quarterly operating results are subject to substantial <font color="blue">fluctuations</font> and     you should not <font color="blue">rely on them as</font> an <font color="blue">indication</font> of our future results     Our quarterly operating results may vary <font color="blue">significant</font>ly due to a <font color="blue">combination</font>     of factors, many of which are beyond our control</td>
    </tr>
    <tr>
      <td>These factors include:     •   demand for products, which historically has <font color="blue">been lowest</font> in the third     quarter;     •   our ability to meet the demand for our products;     •   <font color="blue">increased competition</font>;     •   the number, timing and significance of <font color="blue">new products</font> and product     <font color="blue">introduction</font>s and <font color="blue">enhancements by us</font> and our <font color="blue">competitors</font>;     •   our ability to develop, introduce and <font color="blue">market new</font> and <font color="blue">enhanced versions</font>     of our <font color="blue">products on</font> a <font color="blue">timely basis</font>;     •   changes in <font color="blue">pricing policies by us</font> and our <font color="blue">competitors</font>;     •   changes in the <font color="blue">treatment practices</font> of <font color="blue">orthopaedic surgeons</font>;     •   changes in <font color="blue">distributor <font color="blue">relationships</font></font> and <font color="blue">sales force size</font> and     <font color="blue">composition</font>;     •   the timing of material expense- or income-generating events and the     related <font color="blue">recognition</font> of their <font color="blue">associated financial impact</font>;     •   the timing of <font color="blue">significant</font> orders and shipments;     •   <font color="blue">availability</font> of <font color="blue">raw materials</font>;     •   work stoppages or strikes in the <font color="blue">health care industry</font>;     •   changes in FDA and foreign <font color="blue">governmental</font> <font color="blue">regulatory</font> policies,     <font color="blue">requirement</font>s and <font color="blue">enforcement</font> practices;                                         21       _________________________________________________________________    [48]Table of <font color="blue">Contents       </font>•   changes in <font color="blue">accounting policies</font>, estimates, and <font color="blue">treatments</font>; and     •   <font color="blue">general economic factors</font></td>
    </tr>
    <tr>
      <td>We  believe  that  our  <font color="blue">quarterly sales</font> and operating results may vary     <font color="blue">significant</font>ly in the future and that period-to-period comparisons of our     results of <font color="blue">operations</font> are not <font color="blue">necessarily meaningful</font> and should not be     relied upon as <font color="blue">indication</font>s of <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that     our <font color="blue">sales will increase</font> or be sustained in <font color="blue">future period</font>s or that we will be     profitable in any <font color="blue">future period</font></td>
    </tr>
    <tr>
      <td>Any shortfalls in sales or <font color="blue">earnings from</font>     levels expected <font color="blue">by securities</font> or <font color="blue">orthopaedic industry analysts could</font> have an     immediate and <font color="blue">significant</font> adverse effect on the <font color="blue">trading price</font> of our common     stock in any <font color="blue">given period</font></td>
    </tr>
    <tr>
      <td>We rely on our independent sales <font color="blue">distributors</font> and <font color="blue">sales representatives</font> to     market and sell our products     Our success depends largely upon marketing <font color="blue">arrangements</font> with independent     sales <font color="blue">distributors</font> and <font color="blue">sales representatives</font>, in particular their sales and     <font color="blue">service expertise</font> and <font color="blue"><font color="blue">relationships</font> with</font> the customers in the marketplace</td>
    </tr>
    <tr>
      <td><font color="blue">Independent </font><font color="blue">distributors</font> and <font color="blue">sales representatives</font> may terminate their     <font color="blue"><font color="blue">relationships</font> with</font> us or devote insufficient <font color="blue">sales efforts</font> to our products</td>
    </tr>
    <tr>
      <td>We  do  not  control  our independent <font color="blue">distributors</font> and they may not be     successful in <font color="blue">implementing</font> our marketing plans</td>
    </tr>
    <tr>
      <td>Our failure to maintain our     existing  <font color="blue">relationships</font>  with  our  independent <font color="blue">distributors</font> and sales     <font color="blue">representatives could</font> have an adverse effect on our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Similarly,     our failure to recruit and retain <font color="blue">additional</font> skilled independent sales     <font color="blue">distributors</font> and <font color="blue">sales representatives</font> could have an adverse effect on our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have experienced <font color="blue">turnover with</font> some of our independent     <font color="blue">distributors</font> in the past which <font color="blue"><font color="blue">adversely</font> affected</font> short-term financial     results while we <font color="blue">transitioned</font> to new independent <font color="blue">distributors</font></td>
    </tr>
    <tr>
      <td>While we     believe these <font color="blue">transitions</font> have been managed <font color="blue">effective</font>ly, similar <font color="blue">occurrences</font>     could happen in the future with <font color="blue">different</font> results <font color="blue">which could</font> have a greater     adverse effect on our <font color="blue">operations</font> than we have <font color="blue">previously</font> experienced</td>
    </tr>
  </tbody>
</table>